New hope for tough esophageal cancers: experimental drug combos show promise
NCT ID NCT05342636
Summary
This study tested several new drug combinations for people with advanced esophageal cancer that had worsened after one prior treatment. Researchers enrolled 90 participants to evaluate whether adding experimental drugs to existing immunotherapy (pembrolizumab) with chemotherapy or another drug (lenvatinib) could better control the cancer. The main goals were to check safety and see how well these combinations shrank tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Acibadem Altunizade Hospital-Oncology ( Site 1407)
Üsküdar / İstanbul, Istanbul, 34662, Turkey (Türkiye)
-
Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 1417)
Adana, 01140, Turkey (Türkiye)
-
Aichi Cancer Center Hospital ( Site 1702)
Nagoya, Aichi-ken, 464-8681, Japan
-
Akdeniz Universitesi Hastanesi-Medical Oncology ( Site 1410)
Antalya, 07059, Turkey (Türkiye)
-
Ankara City Hospital-Medical Oncology ( Site 1405)
Ankara, 06800, Turkey (Türkiye)
-
Asan Medical Center-Department of Oncology ( Site 1901)
Seoul, 05505, South Korea
-
Atatürk Üniversitesi-onkoloji ( Site 1416)
Erzurum, 25070, Turkey (Türkiye)
-
Centre Hospitalier Régional Universitaire de Brest - Hôpital Morvan ( Site 1104)
Brest, Finistere, 29200, France
-
Chang Gung Medical Foundation-Linkou Branch ( Site 2006)
Taoyuan District, 333, Taiwan
-
Chang Gung Memorial Hospital at Kaohsiung ( Site 2003)
Kaohsiung Niao Sung Dist, Kaohsiung, 83301, Taiwan
-
Charité Campus Virchow-Klinikum-Klinik Hämatologie Onkologie Tumorimmunologie ( Site 2804)
Berlin, 13353, Germany
-
China Medical University Hospital ( Site 2007)
Taichung, 404332, Taiwan
-
Chulalongkorn University ( Site 2104)
Bangkok, Bangkok, 10330, Thailand
-
Clínica las Condes ( Site 2403)
Santiago, Region M. de Santiago, 7591047, Chile
-
FALP-UIDO ( Site 2400)
Santiago, Region M. de Santiago, 7500921, Chile
-
Faculty of Medicine Siriraj Hospital ( Site 2102)
Bangkok, Bangkok, 10700, Thailand
-
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1200)
Milan, Lombardy, 20133, Italy
-
Hacettepe Universite Hastaneleri-oncology hospital ( Site 1402)
Ankara, 06230, Turkey (Türkiye)
-
Hopital Claude Huriez - CHU de Lille ( Site 1100)
Lille, Nord, 59037, France
-
Hospital Nossa Senhora da Conceição ( Site 2301)
Porto Alegre, Rio Grande do Sul, 91350-200, Brazil
-
Hôpitaux Universitaires de Genève (HUG) ( Site 2702)
Geneva, Canton of Geneva, 1211, Switzerland
-
I.E.U. Medical Point Hastanesi-Oncology ( Site 1406)
Izmir, Karsiyaka, İzmir, 009035575, Turkey (Türkiye)
-
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 2300)
São Paulo, São Paulo, 01246-000, Brazil
-
Institut für Klinisch Onkologische Forschung-Klink für Onkologie und Hämatologie ( Site 2801)
Frankfurt am Main, Hesse, 60488, Germany
-
Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (
Milan, 20141, Italy
-
Istituto Oncologico Veneto IRCCS ( Site 1205)
Padua, 35128, Italy
-
Kantonsspital Graubünden-Medizin ( Site 2700)
Chur, Kanton Graubünden, 7000, Switzerland
-
Liga Norte Riograndense Contra o Câncer ( Site 2303)
Natal, Rio Grande do Norte, 59062-000, Brazil
-
Memorial Ankara Hastanesi-Medical Oncology ( Site 1408)
Ankara, 06520, Turkey (Türkiye)
-
National Cancer Center Hospital ( Site 1700)
Chuo-ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East ( Site 1701)
Kashiwa, Chiba, 277-8577, Japan
-
National Cheng Kung University Hospital ( Site 2001)
Tainan, 704, Taiwan
-
National Taiwan University Hospital ( Site 2000)
Taipei, 10002, Taiwan
-
National University Hospital ( Site 1800)
Singapore, South West, 119074, Singapore
-
Oslo universitetssykehus, Radiumhospitalet ( Site 2501)
Oslo, 0310, Norway
-
Ospedale San Raffaele-Oncologia Medica ( Site 1206)
Milan, Lombardy, 20132, Italy
-
Pitie Salpetriere University Hospital ( Site 1102)
Paris, Orne, 75013, France
-
Saitama Prefectural Cancer Center ( Site 1703)
Ina-machi, Saitama, 362-0806, Japan
-
Samsung Medical Center-Division of Hematology/Oncology ( Site 1900)
Seoul, 06351, South Korea
-
Shizuoka Cancer Center ( Site 1704)
Nagaizumi-cho,Sunto-gun, Shizuoka, 411-8777, Japan
-
Songklanagarind hospital ( Site 2105)
Hat Yai, Changwat Songkhla, 90110, Thailand
-
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1403)
Istanbul, 34722, Turkey (Türkiye)
-
Taichung Veterans General Hospital-Radiation Oncology ( Site 2008)
Taichung, 407, Taiwan
-
Taipei Veterans General Hospital ( Site 2005)
Taipei, 112, Taiwan
-
Universitaetsklinikum Carl Gustav Carus Dresden-Medical Dept I - Medical Oncology ( Site 2806)
Dresden, Saxony, 01307, Germany
-
Universitaetsklinikum Duesseldorf ( Site 2802)
Düsseldorf, North Rhine-Westphalia, 40225, Germany
Conditions
Explore the condition pages connected to this study.